SCHEMBL4515587

SCHEMBL4515587

O=C(Nc1ccc(F)c(F)c1)N1CC(c2nc3c(cnn3-c3ccccc3)c(=O)[nH]2)C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYK2 P29597 1/20 0.46
PDE5A O76074 2/20 0.44
PTGS2 P35354 2/20 0.44
KCNJ6 P48051 3/20 0.43
KCNJ5 P48544 3/20 0.43
KCNJ3 P48549 3/20 0.43
PDE9A O76083 2/20 0.42
ALDH1A1 P00352 4/20 0.42
HPGD P15428 3/20 0.42
TSHR P16473 2/20 0.42
HTT P42858 1/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
ATM Q13315 1/20 0.41
MAPK1 P28482 1/20 0.41
DAPK3 O43293 1/20 0.41
PIM1 P11309 1/20 0.41
PIM3 Q86V86 1/20 0.41
ESR1 P03372 1/20 0.40
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4502029 0.90 POLB (0.49) TYK2PDE5APTGS2PDE9AALDH1A1
SCHEMBL4510948 0.89 TYK2 (0.53) TYK2PDE5APTGS2PDE9AALDH1A1
SCHEMBL4520993 0.88 GRIN2B (0.48) TYK2PDE5APTGS2KCNJ6KCNJ5
SCHEMBL4516468 0.88 TYK2 (0.51) TYK2PDE5APTGS2PDE9AALDH1A1
SCHEMBL4515391 0.86 TYK2 (0.46) TYK2PDE5APTGS2PDE9AALDH1A1
SCHEMBL4514570 0.84 PDE9A (0.61) TYK2PDE5APDE9AALDH1A1TSHR
SCHEMBL4512344 0.84 TYK2 (0.48) TYK2PDE5APTGS2PDE9AALDH1A1
SCHEMBL4505445 0.84 TYK2 (0.46) TYK2PDE5APTGS2PDE9AALDH1A1
SCHEMBL4511659 0.84 PDE9A (0.50) TYK2PDE5APTGS2PDE9AALDH1A1
SCHEMBL4513622 0.84 PDE9A (0.48) TYK2PDE5APTGS2PDE9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137549-A1 Novel compounds useful for the treatment of degenerative & inflamatory diseases GALAPAGOS NV (BE) 2009-05-28 US claimed
WO-2008055959-A1 NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES GALAPAGOS N.V. (BE) 2008-05-15 WO claimed
US-11166956-B2 Combinations of PDE1 inhibitors and NEP inhibitors INTRA-CELLULAR THERAPIES, INC. (US) 2021-11-09 US disclosed
US-20190275046-A1 NOVEL COMBINATION INTRA-CELLULAR THERAPIES, INC. (US) 2019-09-12 US disclosed
US-10285992-B2 Combinations of PDE1 inhibitors and NEP inhibitors and associated methods INTRA-CELLULAR THERAPIES, INC. (US) 2019-05-14 US disclosed
US-20160038494-A1 NOVEL COMBINATION INTRA-CELLULAR THERAPIES, INC. 2016-02-11 US disclosed
US-20090137549-A1 Novel compounds useful for the treatment of degenerative & inflamatory diseases GALAPAGOS NV (BE) 2009-05-28 US disclosed
WO-2008055959-A1 NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES GALAPAGOS N.V. (BE) 2008-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160038494-A1 NOVEL COMBINATION PDE5A, PDE2A, PDE3A TYK2 4707/4885PDE5A 1/4885PTGS2 164/4885
US-10285992-B2 Combinations of PDE1 inhibitors and NEP inhibitors and associated methods PDE5A, PDE3A, PDE2A TYK2 4749/4885PDE5A 1/4885PTGS2 160/4885
US-20090137549-A1 Novel compounds useful for the treatment of degenerative & inflamatory diseases PDE4A, PDE7B, PDE4B TYK2 3816/4885PDE5A 7/4885PTGS2 138/4885
US-20190275046-A1 NOVEL COMBINATION PDE5A, PDE2A, PDE3A TYK2 4707/4885PDE5A 1/4885PTGS2 164/4885
US-11166956-B2 Combinations of PDE1 inhibitors and NEP inhibitors PDE5A, ECE1, PDE3A TYK2 4759/4885PDE5A 1/4885PTGS2 199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.